Ollin Biosciences to Participate in Two Upcoming Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)-- Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that Company management will participate in the private company tracks of two upcoming investor conferences.

Piper Sandler Biopharma Symposium

1x1 Meetings: Wednesday, April 15, 2026
Location: Boston, MA

UBS Private Biotech Summit

1x1 Meetings: Monday, May 18, 2026
Location: New York, NY

About Ollin Biosciences

Established in 2023, Ollin BiosciencesTM is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260408503553/en/

Media & Investors:
Katie Engleman
1AB
[email protected]

Source: Ollin Biosciences, Inc.

You May Also Be Interested In

• Forescout Partners with the White House and the State of Texas for Project Watershed 250 to Give Water Utilities World-Class Cyber Defense Capabilities
• NKB Inc.: Limited Edition: High-Definition Giclée Prints of Katsuhiro Otomo’s Ginza Station Public Art “Procession Spin” Now Available
• S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline